COMPOSITIONS ET METHODES POUR TRAITER UNE MALADIE INFLAMMATOIRE DE L'INTESTIN ET DES MALADIES ET DES AFFECTIONS PROVOQUEES PAR OU ASSOCIEES A FUSOBACTERIUM
Provided herein are pharmaceutical compositions, therapeutic combinations, devices and methods for treating, ameliorating, reversing, causing the remission of, and/or preventing (acting as a prophylaxis, or preventing the initiation of) an inflammatory bowel disorder (IBD) or inflammatory bowel disease (IBD), Ulcerative Colitis； Crohn's disease； J-pouch； fistulising Crohn's disease； a Colitis which can be microscopic, lymphocytic or collagenous； an eosinophilic colitis； indeterminate colitis； idiopathic colitis； diverticulosis and diverticulitis； relapsing diverticulitis； constipation associated inflammatory bowel disease and/or small intestinal bacterial overgrowth； Irritable Bowel Syndrome (IBS) with or without diarrhoea, constipation or pain predominant IBS； periodontitis； rheumatoid arthritis； respiratory infections, appendicitis, vascular disorders such as thrombophlebitis； bacteremia； osteomyelitis； septic shock； Alzheimer's disease； Lemierre syndrome (postanginal sepsis)； colonic polyps or adenomas (optionally hyperplastic, adenomatous or serrated adenomas) or preventing the growth of colonic polyps or adenomas, bowl cancer, or metastases (optionally preventing the initiation or promotion of bowl cancer or metastasis)； pharyngitis； otitis； sinusitis； and any disease, symptom or condition caused or exacerbated by a Fusobacteria (optionally, a F. nucleatum or F. varium) infection. In alternative embodiments, pharmaceutical compositions comprise rifaximin alone or in combination with other antibiotics or drugs.
